



THE SENATE

COMMUNITY AFFAIRS REFERENCES COMMITTEE

Equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer

**PUBLIC HEARING
Wednesday 31 January 2024**

**Corinthian Room, Sydney Masonic Centre
66 Goulburn St, Sydney**

Time	Witness
9.30 am	Cancer Council Australia (<i>Submission 4</i>) Ms Megan Varlow, Director, Cancer Control Policy Rare Cancers Australia (<i>Submission 3</i>) Ms Christine Cockburn, Chief Executive Officer
10.30 am	Head and Neck Cancer Australia (<i>Submission 19</i>) Ms Nadia Rosin, Chief Executive Officer Ms Carolyn Smith, Board Director Mr Matthew Magarey, Board Director (via teleconference) Neuroblastoma Australia (<i>Submission 58</i>) Ms Lucy Jones, Chief Executive Officer Leukaemia Foundation (<i>Submission 39</i>) Mr Tim Murphy, General Manager of Blood Cancer Partnerships
11.30 am	Cancer Assistance Network Mrs Emma Phillips, Executive Director Ms Majella Gallagher, Advocacy and External Relations Australian Cancer Atlas Dr Peter Baade, Senior Manager, Descriptive Epidemiology Dr Kerrie Mengersen, Distinguished Professor, Centre for Data Science Private Cancer Physicians of Australia (<i>Submission 4</i>) Associate Professor Christopher Steer, President
12.15 pm	Break
12.30 pm	Professor Matthew Dun Australian DIPG families
1.10 pm	Lived experience panel
1.30 pm	Lunch

COMMUNITY AFFAIRS REFERENCES COMMITTEE

Equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer

2.15 pm	<p>Children's Cancer Institute (<i>Submission 6</i>) Dr Peter Wejbora, Director, Research Development and Partnerships Dr Emily Mould, Head of Business Development Ms Anastasia Glushko, Stakeholder Engagement Manager</p> <p>Sydney Children's Hospital Network (<i>Submission 14</i>) Dr Richard Mitchell, Director Dr Luciano Dalla-Pozza, Senior Staff Specialist, Director - Cancer Centre for Children Associate Professor Antoinette Anazodo, Paediatric and Adolescent Oncologist</p>
3.15 pm	<p>Clinical Oncology Society of Australia (<i>Submission 4</i>) Dr David Chan, Chair, Neuroendocrine Tumours Group</p> <p>Daffodil Centre and the University of Sydney Cancer Research Network (<i>Submission 32</i>) Professor Karen Canfell, Director, The Daffodil Centre; Stream lead, Cervical Cancer and HPV Professor Anna de Fazio AM, Sydney West Chair in Translational Cancer Research Professor Stephen Clarke</p> <p>Associate Professor Kathy Tucker AO FRACP (<i>Submission 36</i>)</p>
4.15 pm	Break
4.30 pm	<p>Roche (<i>Submission 9</i>) Mr Ben Robinson, Head, Access and Innovation Dr Richard Woodfield, Country Medical Director</p> <p>IQVIA (<i>Submission 49</i>) Mr Quentin Bracquart, Head of Payer, Provider and Government Services and Principal, Strategic Insights and Analytics Mr Andrew Sutton, Vice President and General Manger</p> <p>AstraZeneca (<i>Submission 41</i>) Ms Penny George, Director of Corporate Affairs Ms Rachael Anderson, Market Access Director</p>
5.30 pm	Adjournment